Thiomersal free trivalent influenza split vaccine 2003/2004
Biological2 doses, intramuscular injection
NCT Number: NCT00731393
The aim of the present study is to assess the reactogenicity and immunogenicity of a thiomersal-free influenza vaccine. For comparison, a group of subjects is administered the standard formulation of Influsplit SSW® 2003/2004.
Looking for future studies?
Notify Me6 month–6 year
All sexes
Interventional
Phase 3
GSK Investigational Site, Bützow, Mecklenburg-Vorpommern, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 doses, intramuscular injection
2 doses, intramuscular injection
Other names: Thiomersal free trivalent influenza split vaccine 2003/2004
Time frame: On Day 21 (+- 2) after the second vaccination
Time frame: Within 4 days after each vaccination
Time frame: Within 30 days after each vaccination
Time frame: Throughout the study
Time frame: On Day 21 (+- 2), Month 3 and Month 6 after the second vaccination
GlaxoSmithKline
Industry
To Determine the Immunogenicity and Reactogenicity of a Thiomersal Free Trivalent Influenza Split Vaccine 2003/2004 or of GSK Biologicals' Standard Formulation Influsplit SSW®/Fluarix™ 2003/2004 in Children Aged From 6 Months Until 6 Years
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01191853
Healthy Volunteers, Infections
Bethesda, Maryland, United States
View Trial DetailsNCT04794829
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT07737106
Infections, Influenza
Bayan Nur, Inner Mongolia, China
View Trial DetailsNCT06518577
Infections, Influenza
Phoenix, Arizona, United States
View Trial Details